Not applicableNot Yet RecruitingNCT07331259What this trial is testingCHART-C3G/CLNP023B12011Who this might be right forC3 GlomerulopathyComplement-mediated Kidney DiseaseProteinuria Novartis Pharmaceuticals 83
Testing effectiveness (Phase 2)Looking for participantsNCT07522099What this trial is testingChinese Adults With Kidney DiseaseWho this might be right forImmunoglobulin A Nephropathy (IgAN)Complement 3 Glomerulopathy (C3G)IC-MPGN ADARx Pharmaceuticals, Inc. 30
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06786338What this trial is testingSGB-9768 in Patients with Complement-mediated Kidney DiseasesWho this might be right forIgA Nephropathy (IgAN)C3 GlomerulopathyIC-MPGN Suzhou Sanegene Bio Inc. 38
Early research (Phase 1)Study completedNCT07040787What this trial is testingInvestigation of Drug-drug Interaction of HRS-5965 With Clopidogrel and Clarithromycin in Healthy SubjectsWho this might be right forComplement Mediated Glomerular DiseasesHemolytic Anemia Chengdu Suncadia Medicine Co., Ltd. 36
Testing effectiveness (Phase 2)Study completedNCT03124368What this trial is testingA Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGNWho this might be right forC3 GlomerulonephritisDense Deposit DiseaseC3 Glomerulopathy+2 more Alexion Pharmaceuticals, Inc. 6
Testing effectiveness (Phase 2)Ended earlyNCT03459443What this trial is testingA Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471Who this might be right forC3 GlomerulonephritisC3 GlomerulopathyImmune Complex Membranoproliferative Glomerulonephritis+2 more Alexion Pharmaceuticals, Inc. 22
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05517980What this trial is testingEfficacy, Safety, Pharmacokinetics, and Pharmacodynamics of KP104 to Treat GlomerulonephritisWho this might be right forGlomerulonephritis Kira Pharmacenticals (US), LLC. 52
Early research (Phase 1)Study completedNCT03316521What this trial is testingFirst-In-Human Clinical Study of the C3 Complement Inhibitor AMY- 101 in Healthy Male VolunteersWho this might be right forComplement Mediated Diseases Amyndas Pharmaceuticals S.A. 50
Testing effectiveness (Phase 2)Study completedNCT03369236What this trial is testingA Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G)Who this might be right forC3 GlomerulopathyC3 GlomerulonephritisDense Deposit Disease Alexion Pharmaceuticals, Inc. 13
Early research (Phase 1)Study completedNCT06674915What this trial is testingInvestigation of Pharmacokinetics,Safety,and Pharmacodynamics of HRS-5965 in Subjects With Hepatic ImpairmentWho this might be right forComplement Mediated Primary or Secondary Glomerular Diseases Chengdu Suncadia Medicine Co., Ltd. 24
Early research (Phase 1)Study completedNCT06567392What this trial is testingEvaluate the Mass Balance of [14C] HRS-5965 in Healthy Adult Male VolunteersWho this might be right forComplement Mediated Primary or Secondary Glomerular Diseases Chengdu Suncadia Medicine Co., Ltd. 6
Testing effectiveness (Phase 2)Study completedNCT05083364What this trial is testingStudy of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal DiseaseWho this might be right forC3 GlomerulopathyIgA Nephropathy Arrowhead Pharmaceuticals 62